Pramipexole: all 80 studies that test it

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• Pramipexole vs Placebo Treatment in Bipolar Disorder With Anhedonic DepressionRecruitingNCT07664852Phase 3
• Stratified Pharmacological Approaches for Regulating Circuit-Level EffectsRecruitingNCT07022405Phase 2
• Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)RecruitingNCT06611592Phase 2
• Precision Care for Major Depressive DisorderEnrolling by invitationNCT06580041Phase 4
• Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant DepressionRecruitingNCT04936126Phase 4
• Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUDTerminatedNCT04759703Phase 2/3Results posted
• Non-Opioid Pramipexole and PainCompletedNCT03842709Early Phase 1Results posted
• The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-DopaCompletedNCT03521635Phase 4Results posted
• A Phase 3 Study With P2B001 in Subjects With Early Parkinson'sCompletedNCT03329508Phase 3Results posted
• Targeting Cognition in Bipolar Disorder With PramipexoleCompletedNCT02397837Phase 4Results posted
• Imaging Dopamine Release in DepressionCompletedNCT02033369Phase 4Results posted
• The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's DiseaseCompletedNCT01470859Not applicableResults posted
• Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male VolunteersCompletedNCT01214109Phase 1Results posted
• Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) PatientsCompletedNCT01191944Phase 3Results posted
• Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting ConditionsCompletedNCT01074463Phase 1Results posted
• Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting ConditionsCompletedNCT01074450Phase 1Results posted
• Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With PramipexoleTerminatedNCT01066897Phase 4Results posted
• Pramipexole ER vs. Placebo in FibromyalgiaTerminatedNCT00689052Phase 2Results posted
• Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette SyndromeTerminatedNCT00681863Phase 3Results posted
• Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)CompletedNCT00654498Phase 3Results posted
• Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).CompletedNCT00601523Phase 3Results posted
• Cognitive Enhancement in Bipolar DisorderCompletedNCT00597896Phase 4Results posted
• Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PDCompletedNCT00577460Phase 3Results posted
• A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment PeriodCompletedNCT00560508Phase 2/3Results posted
• Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson DiseaseCompletedNCT00558025Phase 3Results posted
• Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD PatientsCompletedNCT00479401Phase 3Results posted
• Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)CompletedNCT00472199Phase 4Results posted
• Pivotal Study in Advanced Parkinsons Disease PatientsCompletedNCT00466167Phase 3Results posted
• A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) PatientsCompletedNCT00402233Phase 4Results posted
• A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.CompletedNCT00390689Phase 3Results posted
• Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)CompletedNCT00321854Phase 4Results posted
• Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive SymptomsCompletedNCT00297778Phase 4Results posted
• Pramipexole Conversion to Ropinirole Controlled Release (CR)CompletedNCT00275275Phase 3Results posted
• Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) PatientsCompletedNCT00144300Phase 4Results posted
• Lexapro and Pramipexole and to Treat Major DepressionCompletedNCT00086307Phase 2Results posted
• A Study in Healthy People to Compare Two Tablet Formulations of PramipexoleCompletedNCT07727785Phase 1
• Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIVSuspendedNCT06705478Phase 2
• Pramipexole to Enhance Social ConnectionsActive, not recruitingNCT06269146Phase 2
• Long-term Efficacy of Pramipexole in Anhedonic DepressionCompletedNCT05825235Phase 3
• Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)WithdrawnNCT05401019Phase 2
• Pramipexole for Anhedonic DepressionCompletedNCT05355337Phase 3
• Treating Leg Symptoms in Women With X-linked AdrenoleukodystrophyActive, not recruitingNCT05003648Phase 4
• Social Decision Making in Parkinson's DiseaseCompletedNCT04249544Phase 1
• Pramipexole and Morphine for Renal ColicCompletedNCT04160520Phase 1/2
• the Efficacy and Safety of Agomelatine in the Patients With Parkinson's DiseaseStatus unknownNCT03977441Phase 4
• Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis PatientsTerminatedNCT03817554Phase 4
• Pramipexole and Emotional ProcessingCompletedNCT03681509Not applicable
• A Study in Patients With Major Depressive DisorderActive, not recruitingNCT03642964Phase 2
• a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by AntipsychoticsCompletedNCT03430596Early Phase 1
• Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male VolunteersCompletedNCT02264132Phase 1
• Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female VolunteersCompletedNCT02262546Phase 1
• Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male VolunteersCompletedNCT02261103Phase 1
• Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's DiseaseCompletedNCT02233023Phase 4
• Pramipexole in Untreated and Levodopa-treated Parkinson's Disease PatientsCompletedNCT02177357Phase 3
• Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's DiseaseCompletedNCT02172573Phase 3
• Autonomic Function and Cardiovascular Risk in Restless Legs SyndromeCompletedNCT02025608Phase 4
• Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's DiseaseCompletedNCT01673724Phase 4
• Pramipexole as a Treatment for Cocaine DependenceCompletedNCT01651377Phase 1
• Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)Status unknownNCT01515774Phase 4
• Efficacy of Pramipexole Extended Release in the Treatment of Essential TremorWithdrawnNCT01441284Phase 3
• Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective DisorderStatus unknownNCT01320982Phase 3
• Pramipexole for Binge Eating DisorderWithdrawnNCT01106053Phase 3
• Bipolar Study of Seroquel XR With Pramipexole DihydrochlorideCompletedNCT00893841Phase 2
• Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's DiseaseCompletedNCT00666653Phase 1
• Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive BehaviorsCompletedNCT00471588Phase 1
• A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's DiseaseCompletedNCT00399477Phase 4
• A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLSCompletedNCT00375284Phase 4
• Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood DisturbancesCompletedNCT00356096Phase 4
• A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLSCompletedNCT00349531Phase 4
• SWITCH:Restless Legs Patients Switched to Ropinirole From PramipexoleCompletedNCT00344994Phase 4
• Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) PatientsCompletedNCT00275457Phase 3
• Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's DiseaseCompletedNCT00240409Phase 3
• Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)CompletedNCT00239486Phase 2
• Effectiveness of Pramipexole for Treatment-Resistant DepressionCompletedNCT00231959Phase 4
• Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs SyndromeCompletedNCT00152997Phase 2
• A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)CompletedNCT00152958Phase 3
• Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs SyndromeCompletedNCT00144209Phase 3
• Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)CompletedNCT00133198Phase 3
• Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's DiseaseCompletedNCT00096720Phase 2
• Clinical Trial of Pramipexole in Bipolar DepressionCompletedNCT00025792Phase 2

← Pramipexole overview